Three Major Patient Advocacy Groups Focused on CMT Research Collaborating on FDA “Voice of the Patient” Report
This CMT Awareness Month, the Charcot-Marie-Tooth Association (CMTA) is proud to join the Muscular Dystrophy Association (MDA) as a sponsor of the Hereditary Neuropathy Foundation (HNF) who will be hosting the Externally-led Patient-Focused Drug Development ...Read more ...
Regenacy Pharmaceuticals Announces Collaboration with the CMTA to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced a collaboration with the CMTA to validate the role of HDAC6 in multiple forms of CMT disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor.Read more ...
CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options
The Charcot-Marie-Tooth Association (CMTA), a patient organization focused on supporting the development of innovative medicines for Charcot-Marie-Tooth (CMT) disease, today announced a strategic partnership with Acceleron Pharma, a Cambridge-based biopharmaceutical company dedicated to developing medicines ...Read more ...
Volunteer Spotlight: Amy Keller
Amy Keller had always known about CMT as it runs in her family. But, as a healthy, active child who grew up into a symptom-free adult, it had never crossed her mind that she, too, ...Read more ...
How Balance Walking Can Help Fitness and Living with CMT
The start of a new year brings resolutions to work on becoming more fit. It can be exciting to start something new, but by mid-January, many of us are asking whether our goals are reasonable ...Read more ...